Sells drug-and-device systems for delivering chemotherapy to the liver to hospitals and treating centers caring for patients with liver cancers.
10-K for FY2025, filed Feb 26, 2026
Hospitals and treating centers buy HEPZATO directly; Delcath counts consigned kits when used in a procedure and advance purchases when delivered. European hospitals buy CHEMOSAT, with sales counted when kits ship.
10-K for FY2025, filed Feb 26, 2026The Company ships and sells HEPZATO directly to hospitals and treating centers based on approved agreements. For certain customers, the…View ↗
Hospitals and treating centers may also elect to purchase HEPZATO prior to a procedure. For these sales, the purchasing hospital or…View ↗
CHEMOSAT is sold directly to hospitals in the European Union and United Kingdom based on contracted rates in an approved contract or sales…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$85.2M
10-K for FY2025, filed Feb 26, 2026
$85.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
CHEMOSAT
Sold outright
|
7.5% |
CHEMOSAT, FY2025
$6.4M Sources
|
Sold outright |
|
HEPZATO KIT
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
93% |
HEPZATO KIT, FY2025
$78.8M Sources
|
Sold outright |
Hospitals and treating centers buy HEPZATO directly under approved agreements; some hold it on consignment. Delcath sells CHEMOSAT directly to hospitals in the EU and UK.
10-K for FY2025, filed Feb 26, 2026
Yes. It kept 3 cents of every revenue dollar as net income in FY2025 and turned 25 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
Increases 2026 Revenue Guidance to a Range of $115 million to $117 millionView ↗
Growing. Revenue grew 24.0x in 4 years, from $3.6M in FY2021 to $85.2M in FY2025, about 121% a year.
HEPZATO reaches the U.S. market
HEPZATO moved from an unapproved U.S. product candidate to an FDA-approved treatment sold in the United States for eligible adults with metastatic uveal melanoma.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Feb 26, 2026
Broader clinical program
The older report described plans to study HEPZATO in colorectal and bile-duct cancers; the latest report also describes a breast-cancer trial, broadening its clinical program.
10-K for FY2022, filed Mar 27, 2023 10-K for FY2025, filed Feb 26, 2026Our clinical development program for HEPZATO is comprised of the FOCUS Clinical Trial for Patients with Hepatic Dominant Ocular Melanoma…View ↗
Competes with Immunocore Holdings, Boston Scientific, Medtronic, Merit Medical Systems, Varian Medical Systems, Sirtex Medical, AngioDynamics, IDEAYA Biosciences, and Replimune Group
10-K for FY2025, filed Feb 26, 2026In January 2022, Immunocore Holdings plc announced FDA approval for KIMMTRAK (tebentafusp-tebn) for the treatment of HLA-A *02:01-positive…View ↗
Loading...